Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Key Points: Skeletal muscle–directed expression of FIX-Padua resulted in complete correction of HB phenotype in an inhibitor-prone dog model. Long-term immune tolerance to FIX is sustained over years upon multiple challenges with recombinant FIX protein in 2 HB models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“Clinical trials for HB using adeno-associated viral (AAV) vectors targeting the liver are encouraging, and long-term expression of FIX wild-type (WT) transgene product ranges from 2% to 7% in the normal range.(1,2) However, in all AAV liver–directed trials, an anti–AAV-capsid cellular immune response is a limiting saf…”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“Thus, a comprehensive evaluation showed no immune response to FIX-Padua in a highly provocative scenario, combining the most challenging animal model(8) with a target tissue that is not predisposed to immune tolerance.(22) Moreover, 1 UNC-CH dog (O20) received an inadvertent subtherapeutic dose of the same vector (Fig…”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationGene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Davidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244 · cited 1×
“Sex influences liverdirected AAV gene therapy, with lower efficacy in female compared with male mice, but not in skeletal muscle–directed.(21) The strength of immune tolerance induction was confirmed by multiple challenges with rcFIX-WT protein.”
BackgroundHerzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Self-citationCrudele, J. M., Finn, J. D., Siner, J. I., Martin, N. B., Niemeyer, G. P., Zhou, S., Mingozzi, F., Lothrop, C. D., & Arruda, V. R. (2015) · Blood · doi:10.1182/blood-2014-07-588194 · Cited by 153
Self-citationErtl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Cited by
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Role of animal models in biomedical research: a review
Mukherjee, P., Roy, S., Ghosh, D., & Nandi, S. K. (2022) · Laboratory Animal Research · doi:10.1186/s42826-022-00128-1 · Cited by 502
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Self-citationHyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
Samelson-Jones, B. J., Finn, J. D., George, L. A., Camire, R. M., & Arruda, V. R. (2019) · JCI Insight · doi:10.1172/jci.insight.128683 · Cited by 44
Self-citationEvolutionary Insights Into Coagulation Factor IX Padua and Other High-Specific-Activity Variants
Samelson-Jones, B. J., Finn, J. D., Raffini, L. J., Merricks, E. P., Camire, R. M., Nichols, T. C., & Arruda, V. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2019000405 · Cited by 31
“This is unlikely the scenario for FIX-R338L based on our observation that expression of only 1% normal FIX activity after cFIX-R338L gene therapy was sufficient to prevent bleeding in a HB dog.(15) We and others have recently demonstrated that the high specific activity of FIX-R338L requires FVIIIa cofactor activity.”
BackgroundMethodSelf-citation
Metadata
- Authors
- French, R. A., Samelson-Jones, B. J., Niemeyer, G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., & Arruda, V. R.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2018-03-02
- Volume
- 2
- Issue
- 5
- Pages
- 505-508
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W2789747072
- Cited by
- 21
- References
- 10
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. https://app.cochat.ai/papers/10.1182/bloodadvances.2017015313
- The paper
- French, R. A., Samelson-Jones, B. J., Niemeyer, G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., & Arruda, V. R. (2018). Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Advances. https://doi.org/10.1182/bloodadvances.2017015313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.